Mukka Proteins Intrinsic Value
Mukka Proteins intrinsic value. Mukka Proteins (MUKKA) median intrinsic value is ₹62.78 from 8 valuation models (range ₹18–₹94), vs current price ₹31.39 — +100.0% upside (Trading Below Calculated Value), margin of safety 50.0%. Compare with MUKKA fair value estimate to assess whether the stock is under or overvalued.
MUKKA Valuation Methods Summary — DCF, Graham Number & P/E
Mukka Proteins intrinsic value across 8 models vs current price ₹31.39 — upside/downside and value range per method. For current market price and key ratios, visit Mukka Proteins share price chart.
| Method | Type | Intrinsic Value | Range | Upside/Downside | Details |
|---|---|---|---|---|---|
| P/E Based Valuation | earnings | ₹33.12 | ₹26.50 - ₹39.74 | +5.5% | EPS: ₹2.76, Sector P/E: 12x |
| Book Value Method | asset | ₹78.47 | ₹70.62 - ₹86.32 | +150.0% | Book Value/Share: ₹176.33, P/B: 1.0x |
| Revenue Multiple Method | revenue | ₹62.78 | ₹56.50 - ₹69.06 | +100.0% | Revenue/Share: ₹510.67, P/S: 0.8x |
| EBITDA Multiple Method | earnings | ₹62.78 | ₹56.50 - ₹69.06 | +100.0% | EBITDA: ₹148.00Cr, EV/EBITDA: 6x |
| PEG Ratio Method | growth | ₹17.66 | ₹15.89 - ₹19.43 | -43.7% | EPS Growth: 8.0%, Fair P/E: 6.4x |
| Growth Adjusted P/E | growth | ₹22.74 | ₹20.47 - ₹25.01 | -27.6% | Revenue Growth: 6.0%, Adj P/E: 8.2x |
| ROE Based Valuation | profitability | ₹62.78 | ₹56.50 - ₹69.06 | +100.0% | ROE: 15.9%, P/E Multiple: 14x |
| Graham Defensive Method | conservative | ₹94.17 | ₹84.75 - ₹103.59 | +200.0% | EPS: ₹2.76, BVPS: ₹176.33 |
MUKKA Intrinsic Value vs Market Price — All Valuation Models
Mukka Proteins fair value range ₹18–₹94 vs current market price ₹31.39 across 8 valuation models. Read MUKKA ex-dividend dates for the complete payout history and dividend yield track record.
MUKKA Intrinsic Value Analysis — Undervalued or Overvalued?
Mukka Proteins median intrinsic value ₹62.78, current price ₹31.39 — Trading Below Calculated Value by 100.0%, margin of safety 50.0%.
What is the intrinsic value of MUKKA?
Based on our comprehensive analysis using 8 different valuation methods, the estimated intrinsic value of Mukka Proteins (MUKKA) is ₹62.78 (median value). With the current market price of ₹31.39, this represents a +100.0% variance from our estimated fair value.
The valuation range spans from ₹17.66 to ₹94.17, indicating ₹17.66 - ₹94.17.
Is MUKKA undervalued or overvalued?
Based on our multi-method analysis, Mukka Proteins (MUKKA) appears to be trading below calculated value by approximately 100.0%.
MUKKA Financial Health — Key Ratios vs Industry Benchmarks
Mukka Proteins financial ratios — ROE, debt-to-equity, profit margins and liquidity vs industry benchmarks and their impact on intrinsic value.
| Financial Metric | Current Value | Industry Benchmark | Assessment | Impact on Valuation |
|---|---|---|---|---|
| Current Ratio | 29.98 | Industry Standard: 2.0+ | Above 2.0 | Measures short-term liquidity capacity |
| Return on Equity | 15.9% | Industry Standard: 15%+ | Above 15% | Measures shareholder return efficiency |
| Operating Margin | 6.0% | Industry Standard: 20%+ | Below 10% | Indicates operational efficiency level |
| Asset Turnover Ratio | 0.95x | Industry Standard: 1.0x+ | Above 0.5x | Measures asset utilization efficiency |
MUKKA Cash Flow Quality — Operating & Free Cash Flow
Mukka Proteins operating cash flow, free cash flow, quality rating and sustainability score by period — key inputs to DCF intrinsic value calculation.
| Period | Operating Cash Flow | Free Cash Flow | Cash Flow Quality | Sustainability Score |
|---|---|---|---|---|
| March 2026 | ₹-111 Cr | ₹-184 Cr | Negative Cash Flow | 3/10 |
| March 2025 | ₹-112 Cr | ₹-130 Cr | Negative Cash Flow | 3/10 |
| March 2024 | ₹-150 Cr | ₹-174 Cr | Negative Cash Flow | 3/10 |
| March 2023 | ₹-56 Cr | ₹-58 Cr | Negative Cash Flow | 3/10 |
| March 2022 | ₹5 Cr | ₹-1 Cr | Positive Operating Cash Flow | 6/10 |